ARTV Stock Price, Performance & Company Data

13:30

15:10

16:45

18:25

20:00

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Ticker: $ARTV
Sector: Health

Primary listing: NASDAQ
Employees: 115

Headquarters: San Diego, United States
Website: www.artivabio.com

ARTV Metrics

BasicAdvanced

$564m

-$3.21

2.18

Bulls say / Bears say

The U.S. FDA granted Regenerative Medicine Advanced Therapy designation to AlloNK® plus rituximab for the treatment of refractory rheumatoid arthritis, securing an expedited development and review pathway under RMAT. (Reuters)

Initial Phase 2a basket-trial data showed a 71% ACR50 response at six months in refractory RA patients treated with AlloNK + rituximab, with no reported cytokine release syndrome or neurotoxicity, highlighting favorable efficacy and safety. (Reuters)

Artiva priced a $300 million underwritten follow-on equity offering at $11.52 per share and pre-funded warrants, bolstering its cash position and, alongside FDA RMAT designation, is expected to extend its financial runway into 2029. (Reuters) (Reuters)

Artiva’s Q1 FY26 net loss widened to $23.5 million (or $0.95 per share) from $20.3 million (or $0.83) year-over-year, reflecting escalating development expenses. (Reuters)

Cash, cash equivalents and investments declined to $86.8 million as of March 31, 2026, providing runway only into Q2 2027 absent further fundraising. (Reuters)

The May 2026 follow-on offering’s issuance of 23.87 million common shares and 2.17 million pre-funded warrants at $11.52 carries significant dilution risk for existing shareholders. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 18 Jul 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

Artiva’s Q1 FY26 net loss widened to $23.5 million (or $0.95 per share) from $20.3 million (or $0.83) year-over-year, reflecting escalating development expenses. (Reuters)

Cash, cash equivalents and investments declined to $86.8 million as of March 31, 2026, providing runway only into Q2 2027 absent further fundraising. (Reuters)

The May 2026 follow-on offering’s issuance of 23.87 million common shares and 2.17 million pre-funded warrants at $11.52 carries significant dilution risk for existing shareholders. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 18 Jul 2026.

About Artiva Biotherapeutics, Inc.

ARTV Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Buy $ARTV

Lightyear

Legal

Work with us

Bulls say / Bears say

Artiva Biotherapeutics, Inc./$ARTV

About Artiva Biotherapeutics, Inc.

ARTV Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Bulls say / Bears say